CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Gayathri Udyawar
/ Categories: Trending, Markets

USFDA grants tentative approval for generic Tadalafil Tablets

Leading pharma company Lupin Limited receives tentative FDA approval for generic Tadalafil Tablets of USP, 2.5 mg, 5 mg, 10 mg, and 20 mg.

 

The United States Food and Drug Administration (USFDA) gave its tentative approval to market a generic version of Eli Lilly and Company's Galls Tablets in that country.

 

Tadalafil Tablet is the generic version of Eli Lilly's Cialis Tablets. The medication is indicated for the treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia. The annual sales for the drug is approximately US$ 1,949.2 million in the US market, according to IQVIA MAT April 2018 data.

 

Lupin Limited is a transnational pharma company engaged in the manufacturing of branded and generic formulations, biotech products and APIs.

 

On Thursday, the stock of Lupin closed at Rs. 795.25 per share, down by Rs 14.55 or 1.80 per cent on BSE. While the benchmark index BSE Sensex closed marginally down at 36,351.23, down by 22.21 points or 0.06 per cent.

Previous Article Query Board
Next Article Kerbside
Print
1892 Rate this article:
3.7
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR